In Segment C, members will get ABBV-744 and oral navitoclax. In Section D, members will obtain ABBV-744 and ruxolitinib. Contributors will get treatment till ailment progression or perhaps the members are not able to tolerate the study drugs. Ubiquitin-similar proteins that control The soundness of crucial super enhancer-mediated proteins have https://albertj655xju9.wikimeglio.com/user